Success Metrics

Clinical Success Rate
70.0%

Based on 7 completed trials

Completion Rate
70%(7/10)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
3(23%)

Phase Distribution

Ph not_applicable
5
38%
Ph phase_4
7
54%

Phase Distribution

0

Early Stage

0

Mid Stage

7

Late Stage

Phase Distribution12 total trials
Phase 4Post-market surveillance
7(58.3%)
N/ANon-phased studies
5(41.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

70.0%

7 of 10 finished

Non-Completion Rate

30.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Active(1)
Completed(7)
Terminated(3)
Other(2)

Detailed Status

Completed7
Terminated3
unknown2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
70.0%
Most Advanced
Phase 4

Trials by Phase

Phase 47 (58.3%)
N/A5 (41.7%)

Trials by Status

not_yet_recruiting18%
completed754%
unknown215%
terminated323%

Recent Activity

0 active trials
Showing 5 of 13
not_yet_recruitingnot_applicable

Noninferiority Trial Of Sirolimus With Ascorbic Acid Versus Everolimus in All-comers

NCT07566091
unknownphase_4

Comparison of the Efficacy of Paclitaxel-releasing Balloon Catheter System Versus the Everolimus-Eluting Stent System for Treatment of In-Stent Restenosis Lesions - Harmonizing Optimal Strategy for Treatment of In-Stent Restenosis Lesions (The HOST-ISR Trial) -

NCT01093300
terminatednot_applicable

Bioresorbable Vascular Scaffolds Versus Stents in Patients With Chronic Total Occlusion

NCT02739685
terminatednot_applicable

BES, EES, and ZES-R in Real World Practice

NCT01397175
terminatednot_applicable

Bypass Surgery Versus Everolimus-Eluting Stent Implantation for Multivessel Coronary Artery Disease (BEST)

NCT00997828
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT07566091Not Applicable

Noninferiority Trial Of Sirolimus With Ascorbic Acid Versus Everolimus in All-comers

Not Yet Recruiting
NCT01093300Phase 4

Comparison of the Efficacy of Paclitaxel-releasing Balloon Catheter System Versus the Everolimus-Eluting Stent System for Treatment of In-Stent Restenosis Lesions - Harmonizing Optimal Strategy for Treatment of In-Stent Restenosis Lesions (The HOST-ISR Trial) -

Unknown
NCT02739685Not Applicable

Bioresorbable Vascular Scaffolds Versus Stents in Patients With Chronic Total Occlusion

Terminated
NCT01397175Not Applicable

BES, EES, and ZES-R in Real World Practice

Terminated
NCT00997828Not Applicable

Bypass Surgery Versus Everolimus-Eluting Stent Implantation for Multivessel Coronary Artery Disease (BEST)

Terminated
NCT02738658Phase 4

Comparison of the Vasomotor Function and Myocardial Flow in Patients Treated With Bioresorbable and Metallic Stents at 1 Year

Completed
NCT02770651

Late Stent Strut Apposition and Coverage After Drug-Eluting Stent Implantation by OCT in Patients With AMI

Unknown
NCT01035450Phase 4

Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting Stent Trial

Completed
NCT01303640Phase 4

NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-eluting Stent Trial

Completed
NCT01166685Phase 4

Safety and Efficacy Study Comparing 3 New Types of Coronary Stents

Completed
NCT01186120Phase 4

Everolimus-eluting(PROMUS-ELEMENT) vs. Biolimus A9-Eluting(NOBORI) Stents for Long-Coronary Lesions

Completed
NCT01012869Phase 4

AngiographiC Evaluation of the Everolimus-Eluting Stent in Chronic Total Occlusions - the ACE-CTO Study

Completed
NCT01887704Not Applicable

Effect of Rotablator on Balloon Resistant Calcified Coronary Lesion

Completed

All 13 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
13